<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299545</url>
  </required_header>
  <id_info>
    <org_study_id>2010-A01046-33</org_study_id>
    <nct_id>NCT01299545</nct_id>
  </id_info>
  <brief_title>Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy</brief_title>
  <acronym>PRINT</acronym>
  <official_title>Validation Study of RA-INF-Dx as a Multigene Molecular Test Intended to Aid in the Identification of Patients With Rheumatoid Arthritis Who Are Unlikely to Show an Initial Response to Infliximab and Methotrexate Combination Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TcLand Expression S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Theradis pharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medpharmgene, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>TcLand Expression S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design &amp; Objectives:

      Multi-centre, non-interventional, open-label, non-comparative, prospective cohort study with
      a clinical follow-up between 12 and 14 weeks.

      To determine the performances of the RA-INF-Dx blood test intended to aid in the
      identification of patients with rheumatoid arthritis who are unlikely to show an initial
      response to infliximab and methotrexate combination therapy evaluated according to EULAR
      response criteria.

      Ancillary study objective:

      To constitute a biocollection of samples associated with all clinical and biological data
      collected at inclusion and at the evaluation visit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RA-INF-Dx test is a non invasive in vitro blood test intended to aid in the
      identification of patients with RA who are unlikely to show an initial response to infliximab
      and methotrexate combination therapy.

      The RA-INF-Dx test is indicated for use in patients:

        -  18 years of age or older,

        -  Eligible for a first line biologic therapy with infliximab. The RA-INF-Dx test is
           indicated for use by rheumatologists as a biological basis for guiding infliximab
           treatment prior to its initiation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment difficulties
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the performances of the RA-INF-Dx test to aid in the identification of patients with RA who are unlikely to show an initial response to infliximab and methotrexate combination therapy.</measure>
    <time_frame>Performed at inclusion : blood samples will be taken before the infliximab infusion.</time_frame>
    <description>Statistical relationship between the RA-INF-Dx blood test results and the non-response (evaluated according to EULAR criteria) to infliximab and methotrexate combination therapy will be analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-response to infliximab and methotrexate combination therapy based on American College of Rheumatology (ACR) criteria</measure>
    <time_frame>at the time of the first response evaluation (between the 12th and the 14th week)</time_frame>
    <description>A statistical analysis will be performed in order to evaluate the predictive performances of the test validated in the study primary objective in relation to the non-response to infliximab and methotrexate combination therapy evaluated according to ACR criteria.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">123</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>a single group of patients -200 expected</arm_group_label>
    <description>polyarthrite rhumatoid patients</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood sampling in Paxgene tubes (DNA, RNA) Whole blood sampling in EDTA tubes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from RA eligible to a first biologic therapy for whom the treating
        rheumatologist envisages infliximab therapy will be included in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of Rheumatoid Arthritis

          1. Patient with a confirmed Rheumatoid Arthritis according the American College of
             Rheumatology (ACR) classification criteria.

             Disease Activity

          2. Patient with a DAS28 greater than 3.2.

             Treatment

          3. Patient eligible for a first line TNFα blocking agent treatment with infliximab
             according to the &quot;Summary of Product Characteristics&quot;,

          4. Patient refractory to treatment with at least one classical DMARDs (one of which has
             to be MTX) prescribed according to the international recommendations, i.e. for at
             least 12 weeks at the maximal tolerated dose prior to infliximab treatment and with
             doses which must have been kept stable during the 4 weeks preceding the initiation of
             the infliximab therapy (patients may be included if they have undergone a wash-out
             period using cholestyramine or equivalent subsequent to leflunomide treatment),

          5. Use of oral steroids (≤ 10mg/day of prednisone or equivalent dose of another molecule)
             and/or NSAIDs will be permitted; doses must have been kept stable during the 4 weeks
             preceding the initiation of the infliximab therapy,

             Other criteria

          6. Patient (male or female) at 18 years of age or older at inclusion,

          7. Negative β-HCG pregnancy test, when appropriate according to the patient's age and
             contraceptive method,

          8. Informed consent signed.

        Exclusion Criteria:

          1. Patient having received previous courses of other biologic therapy (TNF blocking
             agents, anti-CD20, anti-CTLA4, IL1 blockers, IL6 blockers and other molecules in
             development),

          2. Patient non eligible to infliximab therapy according to the &quot;Summary of Product
             Characteristics&quot;,

          3. Patient with clinically significant, severe and uncontrolled infectious diseases,

          4. Patient with symptoms of a significant somatic or psychiatric/mental illness,

          5. Patient with other auto-immune diseases (i.e. Inflammatory Bowel Diseases, Systemic
             Lupus Erythematosus, vasculitis, uncontrolled asthma, etc...),

          6. Patient with evidence of cardiac, pulmonary, metabolic, renal, hepatic,
             gastro-intestinal conditions, which, in the opinion of the investigator, may interfere
             with the study,

          7. Pregnancy,

          8. Patient that is participating in a clinical trial or that participated in a previous
             one within 10 weeks prior to study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara MARSAL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Val d'Hebron (Barcelona, Spain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Location n°31</name>
      <address>
        <city>Mississauga - Chow</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°36</name>
      <address>
        <city>Ontario</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°34</name>
      <address>
        <city>Rimouski</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°33</name>
      <address>
        <city>Saskatchewan</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°35</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°41</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°13</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°39</name>
      <address>
        <city>Dreux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°14</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°40</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°37</name>
      <address>
        <city>Paris (Hop Bichat)</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°25</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°38</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°6</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°8</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°7</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°10</name>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°9</name>
      <address>
        <city>Kistarcsa</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°15</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°16</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°17</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°27</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°29</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°30</name>
      <address>
        <city>Panevezys</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°28</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n° 19</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°20</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°22</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°23</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°21</name>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°24</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°26</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°18</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°12</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°11</name>
      <address>
        <city>Piestany</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°3</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Location n°5</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Slovenia</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Anti TNF</keyword>
  <keyword>Infliximab</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>DMARDs</keyword>
  <keyword>Gene expression biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

